Cenla Children's Clinic & Associates
Cenla Children's Clinic & Associates was paid $7.64M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 44% of everything it billed.
33Billing provider infoCENLA CHILDREN'S CLINIC & ASSOCIATES
ALEXANDRIA, LA 71301
ALEXANDRIA, LA 71301
33aNPI1871670752assigned 10/31/2006
33bProvider typeSpecialist
28Total paid$7.64M
24GClaims296,266
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Louisiana
Rank by total paid#8 of 228
Median peer was paid$60K
This provider vs. median128×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,099 | $959K | |
| 2019 | 43,284 | $1.16M | |
| 2020 | 33,335 | $948K | |
| 2021 | 59,024 | $1.26M | |
| 2022 | 43,920 | $1.26M | |
| 2023 | 42,669 | $1.11M | |
| 2024incomplete | 35,935 | $949K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 44% | 56,237 | 41,479 | $3.38M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 11% | 8,871 | 6,541 | $868K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.7% | 15,347 | 12,917 | $590K |
| 87631 | 6.6% | 5,088 | 3,945 | $505K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.2% | 6,741 | 5,767 | $394K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.1% | 5,121 | 4,571 | $316K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.0% | 2,836 | 2,282 | $226K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.6% | 7,419 | 5,041 | $198K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.0% | 11,766 | 10,588 | $151K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 4,544 | 4,144 | $115K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 17,394 | 13,179 | $110K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.4% | 1,698 | 1,529 | $103K |
80 more codes
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.3% | 7,489 | $98K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.1% | 8,110 | $81K |
| 87807 | <1% | 6,115 | $61K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 809 | $52K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 522 | $44K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 17,118 | $41K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 686 | $37K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,386 | $36K |
| 80053 | Comprehensive metabolic panel | <1% | 3,328 | $28K |
| 92551 | <1% | 3,881 | $27K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 1,209 | $23K |
| 87428 | <1% | 609 | $18K | |
| 85027 | <1% | 3,284 | $16K | |
| 90474 | <1% | 1,760 | $15K | |
| 81002 | <1% | 6,321 | $13K | |
| 87430 | <1% | 1,006 | $11K | |
| 80061 | Lipid panel | <1% | 1,077 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,265 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 188 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 662 | $6K |
| 92567 | <1% | 670 | $5K | |
| 99173 | <1% | 3,989 | $5K | |
| 85018 | <1% | 2,671 | $4K | |
| 99401 | <1% | 1,170 | $4K | |
| 86308 | <1% | 1,088 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 656 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,132 | $3K |
| 99443 | <1% | 135 | $2K | |
| 94760 | <1% | 8,317 | $2K | |
| A7016 | Dome and mouthpiece, used with small volume ultrasonic nebulizer | <1% | 688 | $2K |
| 0001A | <1% | 73 | $2K | |
| 83655 | <1% | 212 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 32 | $1K |
| 90677 | <1% | 237 | $1K | |
| 36416 | <1% | 26,362 | $1K | |
| 0002A | <1% | 77 | $1K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 16 | $1K |
| 87400 | <1% | 95 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,566 | $1K |
| 90473 | <1% | 181 | $1K | |
| 95117 | <1% | 113 | $1K | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 652 | $711.89 |
| 99177 | <1% | 1,698 | $567.57 | |
| 69210 | <1% | 29 | $539.93 | |
| 80076 | <1% | 90 | $526.49 | |
| 96127 | <1% | 1,382 | $492.30 | |
| 96380 | <1% | 26 | $386.00 | |
| 99499 | <1% | 29 | $269.00 | |
| 94761 | <1% | 370 | $260.73 | |
| 99406 | <1% | 243 | $200.05 | |
| 99051 | <1% | 12 | $143.64 | |
| 90686 | <1% | 2,819 | $93.67 | |
| 99417 | Prolong home eval add 15m | <1% | 15 | $58.36 |
| A4208 | Syringe with needle, sterile 3 cc, each | <1% | 4,593 | $54.08 |
| 94664 | <1% | 797 | $44.76 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 16 | $43.75 |
| 90647 | <1% | 1,819 | $31.28 | |
| 90656 | <1% | 187 | $22.35 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $6.25 |
| A4206 | Syringe with needle, sterile, 1 cc or less, each | <1% | 418 | $6.03 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 57 | $5.32 |
| 90671 | <1% | 644 | $0.01 | |
| 91307 | 0% | 81 | $0.00 | |
| 90697 | 0% | 383 | $0.00 | |
| 90680 | 0% | 1,833 | $0.00 | |
| 99355 | 0% | 349 | $0.00 | |
| 90723 | 0% | 1,725 | $0.00 | |
| 90620 | 0% | 17 | $0.00 | |
| 90381 | 0% | 15 | $0.00 | |
| 90696 | 0% | 13 | $0.00 | |
| 90651 | 0% | 29 | $0.00 | |
| 90660 | 0% | 146 | $0.00 | |
| 90633 | 0% | 712 | $0.00 | |
| 90670 | 0% | 2,909 | $0.00 | |
| 90672 | 0% | 71 | $0.00 | |
| 90734 | 0% | 80 | $0.00 | |
| 90710 | 0% | 378 | $0.00 | |
| 99080 | 0% | 91 | $0.00 | |
| 91300 | 0% | 141 | $0.00 | |
| 90380 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREDDY, C (PRESIDENT)